Nutrition, metabolism, and cardiovascular diseases : NMCD
-
Nutr Metab Cardiovasc Dis · Oct 2016
ReviewProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Our comprehensive review highlights the drug development and pharmacogenomics leading to the recent approval of PCSK9 inhibitors. We also review the anticipated future advances into the uses of PCSK9 inhibition. ⋯ Despite decades of medical advances, ASCVD remains one of the major causes of morbidity and mortality worldwide. Statin use has multiplied since the validation of LDL hypothesis, however, it is undeniable a more effective and well-tolerated agent is needed in significant number or patients. With the arrival of the era of unprecedented CV protection with PCSK9 inhibition, this exciting new therapy holds a pivotal promise as the future of lipid management. The data available already indicate safety, tolerability and superb efficacy of these agents, which are already changing contemporary cholesterol management. The rapid translation of innovative basic science research into drug development may lead to CV outcomes reduction and confirm that this pathway will become prominently utilized.
-
Nutr Metab Cardiovasc Dis · Oct 2016
Multicenter StudyThe relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory.
In the present population-based study, we aimed to describe the per patient annual healthcare cost of people with diabetes in 2007-2012, to assess the relative burden of diabetes complications and other potential determinants on healthcare costs in the 2012 cohort, and to describe and analyse the determinants of the cost of incident cases diagnosed in 2012. ⋯ The present study provides evidence on the excess of healthcare costs due to diabetes complications in both prevalent and incident cases.
-
Nutr Metab Cardiovasc Dis · Oct 2016
Comparative StudySerum 25-hydroxyvitamin D predicts early recurrent stroke in ischemic stroke patients.
This study was conducted to determine 25-hydroxyvitamin D [25(OH) D] levels in serum, and to investigate their associations with stroke recurrence events in a 3-month follow-up study in Chinese patients with first-ever ischemic stroke. ⋯ Our findings suggest that reduced serum levels of 25(OH) D can predict the risk of early stroke recurrence in patients with first-ever ischemic stroke.